AL002
Early Alzheimer's Disease
Phase 2Active - INVOKE-2 trial enrolled
Key Facts
About Alector
Founded in 2013 and publicly traded on Nasdaq, Alector is on a mission to slow and prevent neurodegenerative diseases by harnessing insights from human genetics, immunology, and neuroscience. The company has built a robust pipeline of potential first- and best-in-class candidates, with its lead program, latozinemab (AL001), in a pivotal Phase 3 trial for frontotemporal dementia and AL101 in Phase 2 for Alzheimer's disease via a major collaboration with GSK. Alector's strategy combines internal R&D with high-value partnerships, supported by a seasoned leadership team with deep expertise in drug discovery and development.
View full company profile